Danofloxacin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Danofloxacin
- DrugBank Accession Number
- DB11393
- Background
Danofloxacin is an antibiotic agent from the family of the fluoroquinolones used in veterinary medicine.
- Type
- Small Molecule
- Groups
- Experimental, Vet approved
- Structure
- Weight
- Average: 357.385
Monoisotopic: 357.148869679 - Chemical Formula
- C19H20FN3O3
- Synonyms
- Danofloxacin
- Danofloxacine
- Danofloxacino
- Danofloxacinum
- External IDs
- A180
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Danofloxacin mesylate 94F3SX3LEM 119478-55-6 APFDJSVKQNSTKF-FXMYHANSSA-N - International/Other Brands
- Advocin
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Fluoroquinolones / N-arylpiperazines / Aminoquinolines and derivatives / Haloquinolines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines / N-alkylpyrrolidines show 14 more
- Substituents
- 1,4-diazinane / Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid show 32 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 24CU1YS91D
- CAS number
- 112398-08-0
- InChI Key
- QMLVECGLEOSESV-RYUDHWBXSA-N
- InChI
- InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1
- IUPAC Name
- 1-cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- SMILES
- [H][C@]12CN(C3=C(F)C=C4C(=O)C(=CN(C5CC5)C4=C3)C(O)=O)[C@]([H])(CN1C)C2
References
- General References
- Haritova AM, Rusenova NV, Parvanov PR, Lashev LD, Fink-Gremmels J: Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys. Vet Res Commun. 2006 Oct;30(7):775-89. [Article]
- Hubschle O, Godinho K, Rowan T, Nicholas R: Danofloxacin treatment of cattle affected by CBPP. Vet Rec. 2004 Sep 25;155(13):403. [Article]
- Froshauer S, Silvia AM, Chidambaram M, Sharma B, Weinstock GM: Sensitization of bacteria to danofloxacin by temperate prophages. Antimicrob Agents Chemother. 1996 Jun;40(6):1561-3. [Article]
- Ramezani AM, Manzoori JL, Amjadi M, Jouyban A: Spectrofluorimetric determination of human serum albumin using terbium-danofloxacin probe. ScientificWorldJournal. 2012;2012:940541. doi: 10.1100/2012/940541. Epub 2012 May 2. [Article]
- Goudah A, Mouneir SM: Disposition kinetics and tissue residues of danofloxacin in Muscovy ducks. Br Poult Sci. 2009 Sep;50(5):613-9. doi: 10.1080/00071660903147416. [Article]
- el-Gendi AY, el-Banna HA, Abo Norag M, Gaber M: Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. Dtsch Tierarztl Wochenschr. 2001 Oct;108(10):429-34. [Article]
- McKellar QA, Gibson IF, McCormack RZ: Pharmacokinetics and tissue disposition of danofloxacin in sheep. Biopharm Drug Dispos. 1998 Mar;19(2):123-9. [Article]
- Chen Y, Rosazza JP, Reese CP, Chang HY, Nowakowski MA, Kiplinger JP: Microbial models of soil metabolism: biotransformations of danofloxacin. J Ind Microbiol Biotechnol. 1997 Nov-Dec;19(5-6):378-84. [Article]
- Atef M, El-Gendi AY, Aziza, Amer MM, Abd El-Aty AM: Some pharmacokinetic data for danofloxacin in healthy goats. Vet Res Commun. 2001 Jul;25(5):367-77. [Article]
- External Links
- KEGG Drug
- D07774
- ChemSpider
- 64439
- 1358488
- ChEMBL
- CHEMBL157548
- ZINC
- ZINC000000607798
- Wikipedia
- Danofloxacin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.738 mg/mL ALOGPS logP 0.33 ALOGPS logP 0.71 Chemaxon logS -2.7 ALOGPS pKa (Strongest Acidic) 5.65 Chemaxon pKa (Strongest Basic) 6.73 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 64.09 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 95.47 m3·mol-1 Chemaxon Polarizability 36.6 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 185.64442 predictedDeepCCS 1.0 (2019) [M+H]+ 188.0024 predictedDeepCCS 1.0 (2019) [M+Na]+ 194.76427 predictedDeepCCS 1.0 (2019)
Drug created at February 25, 2016 18:22 / Updated at April 30, 2021 13:08